GlassScriptPhysician profile
Armita Bijari
NPI 1902802408
$19,131.43
in general payments reported to CMS, 2019-2025
67 companies · $3,680 in 2025
The $3,680 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $1,216 · 2021: $2,799 · 2022: $2,496 · 2023: $3,830 · 2024: $4,569 · 2025: $3,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,916.30 |
| Education | $161.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,954.58 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Biogen, INC. | $1,613.53 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Supernus Pharmaceuticals, INC. | $1,573.98 | 2019-2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $1,492.07 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,343.14 | 2021-2025 | |
| Lilly USA, LLC | $1,066.05 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Mdd US Operations, LLC | $755.24 | 2023-2025 | Apokyn, Gocovri, Qelbree |
| Genentech USA, INC. | $613.87 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Sk Life Science, INC. | $498.15 | 2020-2025 | Xcopri |
| Ucb, INC. | $481.96 | 2020-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Allergan, INC. | $418.06 | 2020-2022 | |
| Pfizer INC. | $413.88 | 2023-2025 | |
| Kyowa Kirin, INC. | $352.05 | 2020-2025 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $347.85 | 2021-2025 | Fycompa |
| Argenx US, INC. | $287.19 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armita Bijari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.